# Lonza

全球 GMP 产能（Lonza 瑞士 Visp/美国、Catalent、Thermo Fisher Patheon），使申办方无需自建工厂即可在区域内生产。

Source: https://cn.bioecon.ru/companies/lonza/
Updated: 2026-06-24

- 国家: Switzerland

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | FY2025瑞士法郎65亿 | https://www.lonza.com/news/2026-01-28-06-30 |
| 产能 | 生物反应器总产能约332,000升（含Vacaville基地） | https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial%20Presentations/20260113_Lonza_JPM_2026_Presentation_Final, https://www.pharmamanufacturing.com/sector/contract-manufacturing/article/55338889/lonzas-available-us-capacity-global-footprint-are-major-competitive-advantages-analysts |
| 产能 | 一次性生物反应器技术最高2,000升，不锈钢生物反应器6,000升至25,000升 | https://www.lonza.com/integrated-biologics/manufacturing, https://www.lonza.com/integrated-biologics/manufacturing/mammalian-drug-manufacturing |
| 认证 | 符合cGMP的设施 | https://www.lonza.com/integrated-biologics/manufacturing, https://www.lonza.com/integrated-biologics/manufacturing/mammalian-drug-manufacturing |
| 监管批准 | 过去5年多来通过14家全球卫生监管机构（含FDA与EMA）80余次现场检查 | https://www.lonza.com/integrated-biologics/manufacturing, https://www.lonza.com/integrated-biologics/manufacturing/mammalian-drug-manufacturing |
| 生产基地 | 全球6-7个cGMP生产基地（分布于三大洲） | https://www.lonza.com/integrated-biologics/manufacturing/mammalian-drug-manufacturing |
| 员工人数 | 20,000名同事 | https://www.lonza.com/ |
| 总部 | 瑞士巴塞尔 | https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial%20Presentations/20260113_Lonza_JPM_2026_Presentation_Final |

独立来源: pharmamanufacturing.com

## 技术

- [内毒素检测系统](https://cn.bioecon.ru/technology/endotoxin-testing-systems/)
- [化学酶法 API 合成（生物催化小分子制造）](https://cn.bioecon.ru/technology/chemoenzymatic-api-synthesis/)
- [培养基制造（B2B 生产设备）](https://cn.bioecon.ru/technology/media-manufacturing-equipment/)
- [生物生产 CDMO/CMO (生物制剂/ATMP/mRNA)](https://cn.bioecon.ru/technology/bioproduction-cdmo-cmo/)
- [用于贴壁细胞培养的微载体](https://cn.bioecon.ru/technology/microcarriers-adherent-cell-culture/)
- [面向市场准入的本地化生产](https://cn.bioecon.ru/technology/local-manufacturing-for-market-access/)